Alpha Teknova, Inc.

Listed Company

TKNOCIK 0001850902NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthIn Vitro & In Vivo Diagnostic SubstancesDelawareFY ends Dec 31

Period

FY 2025

Revenue

$40.52M

Net Income

$-17.26M

Total Assets

$103.58M

Equity

$68.78M

Shares Out

53.59M

Op. Cash Flow

$-8.65M

Business

Alpha Teknova, Inc. is a leading producer of critical reagents used in the discovery, development, and commercialization of therapies, vaccines, and molecular diagnostics. It offers pre-poured media plates, liquid cell culture media and supplements, and molecular biology reagents, including custom and GMP‑grade formulations. Its key business segments comprise Lab Essentials (RUO catalog and custom products) and Clinical Solutions (ISO 13485‑certified GMP offerings). The company sells to pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions across the life sciences market.

Summary from filing dated 2025-03-07

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	41	38	37	41	37
Cost of sales	27	31	26	24	19
Gross profit	13	7	10	17	18
Research and development	2	3	6	8	4
Sales and marketing	7	6	9	9	4
General and administrative	20	23	25	28	20
Amortization of intangible assets	1	1	1	1	1
Total operating expenses	30	33	46	67	30
Loss from operations	−17	−26	−36	−50	−12
Interest expense, net	−710,000	−687,000	−833,000	213,000	−589,000
Other adjustment to loan exit fee	485,000	0	—	—	—
Total other expenses, net	−225,000	−687,000	−2	268,000	−629,000
Loss before income taxes	−17	−27	−37	−49	−13
Provision for (benefit from) income taxes	58,000	−88,000	−298,000	−2	−3
Net loss	−17	−27	−37	−47	−10
Net loss per share - basic	−0.32	−0.57	−1.16	−1.69	−0.61
Net loss per share - diluted	−0.32	−0.57	−1.16	−1.69	−0.61
Weighted average shares used in computing net loss per share - basic	53	47	32	28	16
Weighted average shares used in computing net loss per share - diluted	53	47	32	28	16

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	6	4	28	42	—
Short-term investments, held -to-maturity	15	27	0	—	—
Accounts receivable, net of allowance for credit losses of $23 thousand and $83 thousand as of December 31, 2025 and December 31, 2024, respectively	5	4	4	4	5
Inventories, net	7	7	12	12	5
Prepaid expenses and other current assets	2	1	2	2	2
Total current assets	35	43	46	61	101
Property, plant and equipment, net	42	46	50	52	30
Operating right-of-use lease assets	14	16	16	20	20
Intangible assets, net	12	13	14	18	19
Other non-current assets	1	1	2	2	180,000
Total assets	104	119	129	152	167
Accounts payable	1	825,000	1	2	2
Accrued liabilities	4	5	6	6	6
Current portion of operating lease liabilities	2	2	2	2	0
Current portion of long-term debt	0	4	0	—	—
Total current liabilities	8	11	9	11	8
Deferred tax liabilities	879,000	827,000	919,000	1	3
Other accrued liabilities	0	10,000	102,000	191,000	273,000
Long-term debt, net	13	9	13	22	12
Long-term operating lease liabilities	13	15	15	18	0
Total liabilities	35	36	39	52	23
Commitments and contingencies (Note 15)	—	—	—	—	—
Preferred stock, $0.00001 par value, 10,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively, zero shares issued and outstanding at December 31, 2025 and December 31, 2024	0	0	0	0	0
Common stock, $0.00001 par value, 490,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively, 53,562,154 and 53,409,727 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	1,000	1,000	0	0	0
Additional paid-in capital	205	201	182	155	151
Accumulated deficit	−136	−119	−92	−55	−8
Total stockholders equity	69	82	90	100	143
Total liabilities and stockholders equity	104	119	129	152	167

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Bad debt expense	68,000	130,000	21,000	25,000	235,000
Inventory reserve	2	5	323,000	697,000	441,000
Depreciation and amortization	6	7	6	3	3
Stock-based compensation	3	4	4	4	2
Deferred taxes	52,000	−92,000	−304,000	−2	−3
Accrued interest income on short-term investments	29,000	−69,000	0	—	—
Amortization of discount on short-term investments	−614,000	−344,000	0	—	—
Amortization of debt financing costs	220,000	394,000	498,000	278,000	134,000
Non-cash lease expense	117,000	182,000	137,000	329,000	65,000
Loss on disposal of property, plant, and equipment	19,000	233,000	57,000	—	—
Accounts receivable	−374,000	−494,000	292,000	380,000	−278,000
Inventories	−2	244,000	330,000	−8	−2
Prepaid expenses and other current assets	−567,000	−18,000	131,000	64,000	−1
Other non-current assets	97,000	470,000	400,000	−2	−156,000
Accounts payable	470,000	−594,000	−773,000	572,000	270,000
Accrued liabilities	73,000	−389,000	2	188,000	2
Other	−10,000	−92,000	−89,000	−82,000	—
Cash used in operating activities	−9	−12	−19	−27	−9
Purchases of short-term investments	−17	−30	0	—	—
Maturities of short-term investments	29	4	0	—	—
Proceeds from sale of property, plant, and equipment	0	125,000	197,000	0	—
Purchase of property, plant and equipment	−1	−1	−8	−28	−20
Cash provided by (used in) investing activities	11	−27	−8	−28	−18
Proceeds from equity financing, net	0	15	23	0	—
Proceeds from long-term debt	1	0	—	—	—
Payment of exit fee costs	−1	0	0	−135,000	0
Payment of debt issuance costs	−100,000	−25,000	−47,000	−172,000	−153,000
Proceeds from financed insurance premiums	333,000	385,000	1	0	—
Repayment of financed insurance premiums	−293,000	−738,000	−594,000	0	—
Proceeds from exercise of stock options	100,000	29,000	76,000	145,000	0
Proceeds from issuance of common stock under employee stock purchase plan	111,000	135,000	252,000	294,000	0
Cash provided by financing activities	151,000	15	13	10	111
Change in cash and cash equivalents	2	−25	−14	−45	84
Income taxes paid	2,000	39,000	0	0	8,000
Interest paid, net of amounts capitalized	1	2	2	101,000	414,000
Capitalized property, plant and equipment included in accounts payable and accrued liabilities	149,000	104,000	51,000	2	2
Recognition of operating right-of-use lease asset	262,000	1	−1	22	0
Recognition of operating lease liabilities	262,000	1	−1	22	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro